Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic

Persons with multiple sclerosis (PwMS) have been considered at high risk for vaccination and/or acquisition of COVID-19 related to their reduced immune systems and daily regimen of immune suppressing therapy. Sub-stantiated and unsubstantiated reports on these unknown circumstances increased anxiety and depression. Low -dose naltrexone (LDN) is a potentially effective off-label therapy shown to be effective at controlling fatigue for several autoimmune disorders including MS. This study utilized a small population of PwMS from central Pennsylvania in order to determine whether LDN therapy altered their perceived anxiety or depression during the early months of COVID-19. Utilizing mailed surveys, self-reported anxiety and depression scores were found to be significantly lower for PwMS who were prescribed LDN either alone or as an adjuvant to a standard disease modifying therapy (DMT) in comparison to those on oral disease-modifying therapies (DMTs). The data suggest that the non-toxic, inexpensive biotherapeutic may be beneficial in lessening anxiety.

Automated summary

This study investigated the effects of low-dose naltrexone (LDN) therapy on anxiety and depression levels in persons with multiple sclerosis (PwMS) during the early months of COVID-19. The results showed that PwMS who were prescribed LDN, either alone or as an adjuvant therapy, had significantly lower self-reported anxiety and depression scores compared to those on oral disease-modifying therapies.